SCIO-469 Scios Inc.

Abstract

SCIO-469 is a small-molecule p38 mitogen-activated protein (MAP) kinase inhibitor under development by Scios Inc as a potential oral therapy for inflammatory disorders. By July 2004, SCIO-469 was in phase lib clinical trials for rheumatoid arthritis.

• Authors: Spyros N Nikas, Alexandros A Drosos
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 5 Issue 11 Pg. 1205-12 (Nov 2004) ISSN: 1472-4472 [Print] England
• PMID: 15573872 (Publication Type: Journal Article, Review)

Chemical References

• Enzyme Inhibitors
• Indoles
• SCIO-469
• p38 Mitogen-Activated Protein Kinases

Topics

• Animals
• Arthritis, Rheumatoid (drug therapy)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Enzyme Inhibitors (metabolism, pharmacology, therapeutic use)
• Humans
• Indoles (metabolism, pharmacology, therapeutic use)
• Structure-Activity Relationship
• p38 Mitogen-Activated Protein Kinases (antagonists & inhibitors)